Mobilized peripheral blood progenitor cells (PBPC) have been shown t o provide rapid engraftment in patients given high-dose chemotherapy. PBPC contain cells with long-term engraftment potential as shown in animal models. In this study we have further analyzed mobilized PBPC for their ability t o support serial transplantation of irradiated mice. Transplantation of recombinant human granulocyte colonystimulating factor (rhG-CSF) plus recombinant rat stem cell factor (rrSCF) mobilized PBPC resulted in 989'0 donor engraftment of primary recipients at 12 t o 14 months posttransplantation. Bone marrow (BM) cells from these primary recipients were harvested and transplanted into secondary recipients. At 6 months posttransplantation, all surviving secondary recipients had donor engraftment. Polymerase chain reaction (PCR) analysis showed greater than 909'0 male cells in spleens, thymuses, and lymph nodes. Myeloid colonies from BM cells of secondary recipients demonstrated IGH-DOSE CHEMOTHERAPY for treatment of solid tumors requires cellular support of bone marrow (BM) cells or peripheral blood progenitor cells (PBPC). BM transplantation (BMT) has been shown to provide long-term durable engraftment of recipients. PBPC transplantation has primarily been performed in the autologous setting, complicating the determination of long-term engraftment of donor cells from endogenous recovery. Mouse models have been used to evaluate the long-term engraftment potential of growth factor mobilized PBPC. Granulocyte colony-stimulating factor (rhG-CSF),' stem cell factor (SCF),' and interleukin-l (IL-l)3 mobilized PBPC have been shown to provide donor engraftment in irradiated mice for 6 to 12 months posttransplantation. In addition, we have shown that PBPC mobilized by the combination of an optimal dose of rhG-CSF plus low doses of recombinant rat SCF have increased numbers of cells with short-term and long-term engraftment potential compared with PBPC mobilized with rhG-CSF A number of studies have demonstrated that serial transplantation of BM cells leads to decreased long-term reconstitution ability and that BM cells from previously transplanted animals have decreased long-term reconstituting ability (LTRA) compared with BM cells from untreated anim a l~.~.~ Studies by Harrison et a1 demonstrated that the decline in LTRA was not a function of age of the stem cell^.^^* Moreover, they concluded that the proliferative potential of stem cells was decreased after transplantation, probably because of differentiative pressure on the stem cells. In this study we have evaluated the short-term and long-term reconstituting capacity of BM cells from mice that were transplanted with PBPC mobilized with rhG-CSF alone or the combination of rhG-CSF plus rrSCF. Male donor mice were mobilized for 7 days with growth factors and the PBPC granulocyte/macrophage colony-forming cells (GM-CFC) of male origin in all animals. In comparison, transplantation of rhG-CSF mobilized PBPC resulted in decreased male engraftment in secondary recipients. BM cells from secondary recipients, who originally received PBPC mobilized by the combination of rrSCF and rhG-CSF, were further passaged t o tertiary female recipients. At 6 months posttransplantation, 909'0 of animals had male-derived hematopoiesis by wholeblood PCR analysis. These data showed that PBPC mobilized with rhG-CSF plus rrSCF contained cells that are transplantable and able t o maintain hematopoiesis for more than 26 months, suggesting that the mobilized long-term reconstituting stem cells (LTRC) have extensive proliferative potential and resemble those that reside in the BM. In addition. the data demonstrated increased mobilization of LTRC with rhG-CSF plus rrSCF compared t o rhG-CSF alone.
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MATERIALS AND METHODS
Mice. Eight-to 12-week-old female and male splenectomized (C57BW6J x DBN2J) F, (BDF,) mice were purchased from Charles River Laboratories (Wilmington, MA). All animals were housed at animal facilities of Amgen Inc (Thousand Oaks, CA) under sterile conditions and were supplied with acidified water.
Transplantation. Mobilization of PBPC using BDF, mice has been described previously! Briefly, male splenectomized BDF, mice were treated with rhG-CSF at 200 pgkgld, or rhG-CSF 200 pg/kgl d plus recombinant rat pegylated SCF (rrSCF-PEG) at 25 pg/kg/d for 7 days. Both rhG-CSF and rrSCF-PEG were produced by Amgen Inc.'.'' BM cells from femurs and tibias were flushed in 2% fetal bovine serum-Hanks' balanced saline solution (FBS HBSS), washed, and resuspended in isotonic saline containing 1 % bovine serum albumin (BSA). Nucleated cells were counted and transplanted into yirradiated (GI3', 12 Gy at split dose 4 hours apart) female BDFl mice. Colony assays. Nucleated BM cells, 2 X 104, were plated in 1.0 mL Iscove's modified Dulbecco's medium (IMDM) plus methyl cellulose containing 10% FBS, I % BSA, lipids, transferrin, in~u1in.l~ 2.5 ng/mL rmlL-3, 2.5 ng/mL rhlL-10, 1 0 0 ng/mL rrSCF, 100 ng/ mL rhlL-6, 1 0 0 ng/mL rhIL-11, and 2 UlmL rh erytropoietin (rhEpo). Granulocytelmacrophage (GM) and multilineage colonies were scored after 9 days of incubation in 5% CO2 at 37°C.
Y-chromosome polymerase chain reaction (PCR) analysis. PCR analysis of male-derived hematopoiesis in whole blood and single colonies has been described in detail previously.2 Semi-quantitative PCR was performed on spleens, thymuses, and lymph nodes to measure the percentage of male-derived cells. Briefly, cell suspensions were prepared by breaking spleens, thymuses, and lymphoid nodes in a 100-pm cell strainer (Falcon, Lincoln Park, NJ) with a plunger from a 1.0-mL syringe in 2% FBS HBSS. Cells were than lysed and digested with proteinase K. DNA was extracted by conventional phenol/chloroform methods.I2 One hundred nanograms of DNA was amplified in 200 pL thin-wall tubes (Perkin Elmer Cetus, Norwalk, C T ) in a total volume of 50 pL reaction buffer containing 10 pmol of mouse Y-chromosome-specific primers, or mouse platelet-derived growth factor (PDGF) B receptor specific primers, 1.5 mmol/L MgCI2. 50 mmol/L KCI, 10 mmol/L Tris-HCI, pH 8.3,0.2 mmol/L dNTPs, and 2.5 U Taq polymerase (Boehringer Mannheim, Indianapolis, IN). PCR reaction was initiated at 94°C for 4 minutes, followed by 28 cycles at 94°C for 1 minute, 62°C for 1 minute, and 72°C for 2 minutes. Amplification with Y-specific primers resulted in a 722-bp fragment corresponding to the Sry locus sequence 256-978," whereas amplification with PDGF B receptor primers generated an approximately 750-bp fragment corresponding to mouse PDGF B receptor cDNA sequence 948-1 166, which contains an Mice reconstituted with PBPC mobilized with either rhG-CSF alone or rhG-CSF plus rrSCF were killed at the times indicated. Results of donor (malekderived hematopoiesis are shown by PCR analysis of whole blood and single colonies picked from BM cultures.
intron sequence.I4 Amplified materials were electrophoresed in 1.5% agarose, Southern blotted, and hybridized to 32P-end-labeled Sry or PDGF B receptor internal sequences (25-bp oligos), respectively, with conventional hybridization protocols.I2 An overview of the serial transplantation and analysis is presented in Fig 1. 
RESULTS
PBPC mobilized with rhG-CSF alone (group A) or rhG-CSF plus rrSCF (group B) were transplanted into lethally irradiated mice at 2.5 X IO' low-density cells per animal.
At 48-59 weeks posttransplantation, these mice had greater than 90% donor (male) cells in the peripheral blood ( Table  1) and 81% (group A) and 98% (group B) donor-derived GM-CFC in the BM.* The BM cells from these animals were harvested as described in Materials and Methods and transplanted into secondary female recipients, and these animals were analyzed at 26 weeks posttransplantation ( Table   2) . No difference was observed in the BM cellularities of secondary recipient mice in both groups of animals (data not shown). Mice from groups 1 and 2 had 67% and 73% survival at 40 weeks, respectively, whereas mice in groups 3 and 4 had 87% and 97% survival, respectively ( Table 2) .
Whole-blood PCR analysis of the long-term surviving mice showed 100% of groups 3 and 4 mice were positive for the Y chromosome and 40% and 91% of groups 1 and 2, respectively. PCR analysis was performed on individual colonies picked from BM cultures to assess male-derived hematopoietic precursors in the secondary recipients. This approach is a better estimate of donor-derived hematopoiesis than whole-blood PCR analysis because of variables in whole-blood PCR analysis, such as DNA template copy number, amplification conditions, and the presence of cotransplanted male lymphocytes in circulation, which may be long-lived in vivo.",'6 Large colonies containing approximately greater than IO4 cells were individually picked from cultures under an inverted microscope. Morphologic staining of these colonies showed them to be mainly granulocytes and macrophages, with about 10% of colonies being multilineage. DNA was prepared from each colony individually and amplified with both Y-specific primers and PDGF B receptor primers. Two hundred fifty colonies were analyzed from these secondary recipients (Fig 2) . Mice in groups 1, 2, and 3 had some animals that had Y-chromosome-positive colonies. All mice (10 of 10) in group 4 had Y-chromosomepositive colonies, with 4 mice having 100% of colonies of donor origin (Fig 2) . These data showed a higher frequency of long-term reconstituting cells from mice originally mobilized with rhG-CSF plus rrSCF compared with rhG-CSF alone. Cells in the lymphoid organs of the secondary recipient mice were also analyzed for Y-chromosome-positive cells. Ten mice from group 4 were killed at 6 months posttransplantation. DNA was extracted from spleen, thymus, and lymph node and analyzed by semi-quantitative PCR (Fig 3) . All the lymph nodes, spleens, and thymuses had greater than 90% male-derived DNA. This showed that both myeloid and 2305 lymphoid long-term repopulation originated from the rhG-CSF plus rrSCF mobilized PBPC.
The BM cells from secondary recipients were transplanted into irradiated tertiary female recipients. Ten secondary mice from group 4 (Table 2) were killed at 26 weeks posttransplantation and the BM cells from the femurs and tibias of each mouse were pooled and transplanted into 6 recipient mice. Three mice received 1 X IO6 cells and 3 mice received the remainder of the cells (range 3 to 10 X lo6, mean 6.9 t 1.7 X lo6 cells). At 24 weeks posttransplantation, the tertiary recipients were analyzed for male cells in the peripheral blood. Figure 4 shows the analysis of tertiary recipient mice that were transplanted with 1 X lo6 BM cells. Nineteen of 21 mice were male positive and 15 of 21 mice had greater than 90% male-derived cells in the peripheral blood. All animals transplanted with higher cell numbers similarly had greater than 90% male-derived cells (data not shown).
DISCUSSION
In a previous report we showed that PBPC mobilized by the combination of rhG-CSF plus rrSCF contained cells capable of long-term reconstitution (> 12 months) when transplanted into irradiated recipients.* The data presented in this study analyzed the potential of these mobilized PBPC for reconstitution of secondary and tertiary recipients. A number of studies have demonstrated that G-CSF or SCF alone are able to mobilize cells that provide hematopoiesis for 6 to 14 month^,'"'^ although higher doses of SCF were needed to achieve the same mobilization as G-CSF. The combination of rhG-CSF with a low dose of rrSCF clearly showed synergy in PBPC mobilization?*20 PBPC mobilized by the combination of rhG-CSF plus rrSCF provided more sustained engraftment than PBPC mobilized by rhG-CSF alone. Previous studies by Harrison et a1 using BM cells have shown that durability of LTF2A was related to the dose of BM cells transplanted.8 Sustained donor engraftment through serial transplantation is directly related to the number of stem cells present in the primary transplantation. Therefore, the number of LTRC mobilized by rhG-CSF plus rrSCF must be greater than the number of LTRC mobilized by rhG-CSF alone.
We initially transplanted 2.5 X lo5 low-density cells (equivalent to 20 pL whole blood) into primary recipients. In the secondary transplantation, 1 X lo7 BM cells from primary recipient were transplanted and demonstrated sustained engraftment in both lymphoid and myeloid cells. Therefore, one primary recipient mouse would be able to reconstitute 20 secondary mice, assuming that there are 2.0 X 1 0 ' BM cells in a mouse. In the tertiary transplantation, 1 X lo6 BM cells from the secondary recipients were sufficient to give 90% male-derived blood nucleated cells. Thus, one secondary recipient would be able to reconstitute 200 tertiary recipients. That is, 2.5 X 10' low-density cells from the peripheral blood of rhG-CSF plus rrSCF treated mice would be able to generate 4,000 tertiary recipients with 90% of them having male-derived hematopoiesis. These results suggest that rhG-CSF plus rrSCF mobilized PBPC contain high numbers of LTRC. In addition, 2.5 X 10' peripheral blood low-density cells have provided mature blood cells for over 26 months, demonstrating extensive proliferative potential through the serial transplantation. Whether the LTRC undergo self-renewal is an interesting question and would be consistent with the long-term engraftment generated through tertiary transplantation and potential engraftment of several thousand tertiary recipients.
PDGFBR l m
The potential use of SCF in combination with G-CSF for mobilization of PBPC has been shown in several animal models, including mouse, canine, and These studies demonstrated enhanced short-term engraftment of irradiated animals transplanted with SCF plus G-CSF mobilized PBPC compared with G-CSF alone mobilized PBPC. Based on these studies, clinical trials have been conducted to compare mobilization of PBPC by rhG-CSF alone to mobilization with rhG-CSF plus rhSCF.'3"'1 In breast cancer patients. the combination of rhG-CSF plus rhSCF at doses of IO pg/kg/d or higher resulted in a twofold to threefold increase in PBPC compared with rhG-CSF alone." Transplantation of the PBPC after high-dose chemotherapy resulted in equivalent engraftment in both patient group~.'~ Additional clinical studies are required to determine if the increase in PBPC leads to clinical benefits. The potential use of mobilized PBPC for ex vivo expansion and gene therapy will require optimal CD34 levels in PBPC samples and maximum numbers of cells with long-term engrafting potential.
The data presented in this study support the use of rhG-CSF plus rhSCF mobilizing PBPC in these settings because they would provide increased numbers of mobilized progenitors and long-term engrafting cells.
